Realcan(SZ:002589)2022-12-08 05:24Group 1: Sales Performance - The company's pharmaceutical sales revenue increased by 7.18% in the first half of the year [1] - Online procurement revenue from grassroots medical institutions in Shandong reached 3.37 billion CNY, a year-on-year growth of 22.88%, with a gross profit of 310 million CNY, up 46.58% [1] - Coverage rates for large hospitals and grassroots medical institutions in Shandong exceed 98% and 95%, respectively [1] Group 2: Medical Equipment and Vaccine Growth - Medical equipment revenue reached approximately 138.1 million CNY, showing a year-on-year increase of 202.13% [1] - Vaccine business revenue increased by 268.65% year-on-year [1] - Medical equipment sales are becoming a significant growth point for the company [1] Group 3: Non-Public Offering Plan - The company plans to raise funds through a non-public offering, with major shareholder Zhang Renhua contributing 42.12% of the total [1] - The offering price is set at 40.56 CNY per share, aiming to raise 4 billion CNY, which will be used to supplement working capital after deducting issuance costs [1] - After the offering, the actual controllers Zhang Renhua and Han Xu will hold a combined shareholding of 44.50%, while Huatai Fund will hold 15.90% [1][3] Group 4: Purpose of Fundraising - The company aims to improve cash reserves and financial structure through fundraising, addressing long accounts receivable periods and significant inventory costs [2] Group 5: Major Shareholder's Perspective - Major shareholders Zhang Renhua and Han Xu are optimistic about the company's long-term development, as evidenced by their decision to increase their stake prior to the offering [3]